Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels
I. Kurth, N. Yamaguchi, C. Andreu-Agullo, H. S. Tian, S. Sridhar, S. Takeda, F. C. Gonsalves, J. M. Loo, A. Barlas, K. Manova-Todorova, R. Busby, J. C. Bendell, J. Strauss, M. Fakih, A. J. McRee, , S. F. Tavazoie
RGX-202 inhibits CRC growth by targeting SLC6A8 creatine transporter, reduces creatine and ATP levels, and shows efficacy in multiple tumor models and human trials.
bioRxiv · Apr 26, 2021Cancer Biology